Vernalis Share Discussion Threads

[quraishim] 25/2/2008 11:54

bounty......two days and has risen over 50%......its rerating but dont know about when its going to level off......

[bountyhunter] 25/2/2008 11:46

yes, maybe it will drop back a bit to let me buy some more at a lower price ;)

[quraishim] 25/2/2008 11:44

bounty...yes, me too but this stock is a tart.........teasing all the way.

[bountyhunter] 25/2/2008 11:42

I knew I should have picked up more on Friday, even when the price at that point was at a premium!
We are no.5 on the leader board now.

[quraishim] 25/2/2008 10:44

Piper Jaffray values at 31p.......but i feel the market has a whiff of some corporate activity.....Lord knows what?????

[quraishim] 25/2/2008 10:05

just cannot second guess this stock as we are heading towards in my opinion...25p and Lord knows if a big Pharma(biotech) makes a prempt bid.
In a note to clients this morning Piper Jaffray pointed out that the
departure of chief executive Sturge, along with the cancellation of the debt
obligations, opened the door to potential bids.
However Fellner said that, while he would consider any proposal on its
merits, the company was "building a structure which we feel is robust for the
longer term", and Fellner added that he was trying to raise funds through the
"traditional biotech route of undertaking attractive partnerships".

[bountyhunter] 25/2/2008 09:29

number 14 on the leader board currently:

[bountyhunter] 25/2/2008 09:27

well I couldn't on Friday - glad to be back in in any case!

[quraishim] 25/2/2008 09:25

steady rise....buyers cannot get enough of these........

[bountyhunter] 25/2/2008 09:22

off we go again

[bountyhunter] 24/2/2008 09:47

I wish I could but unfortunately I can't! (not being a premium user)

[quraishim] 24/2/2008 09:32

bounty could u be kind to moderate Immersion's post.............thanks...serial ramping on all threads.

[bountyhunter] 24/2/2008 07:37

qur - good point re the divestment of Apokyn and associated corporate activity

[jweekes] 23/2/2008 23:50

I have been asking around and taking opinions again. All are very positive, and some "opinion makers" are bursting with positivity. It has been hard to get share price opinions as they are not involved the market as such. Sunday meeting will reveal much more hopefully.

[quraishim] 23/2/2008 21:17

This stands out too...."the extensive restructuring of the business, will create a platform that will enable us to rebuild significant shareholder value in the mid-term".

[quraishim] 23/2/2008 21:11

bounty...As ver is in process of divest Apokyn® – currently marketed by Vernalis in the US for Parkinson's disease – and its US commercial operations, detailed discussions of which are currently ongoing with interested parties. This is sign of corporate activity...where during negotiation the yanks might just offer for the whole company as it is cheaper before the complete reorganisation...and if Fellner has a price tag for Apokyn for $50 million than might as well buy VER with all its intellectual rights for $150 million and cop that $40 million cash they will have after accounting for restructuring.....mind out a predator might just take the whole company with all its staff in North America and Canada....but to win an outright bid I feel would be predator might have to cough $200 million, even that is cheap when u consider ver having 25 years of research and development behind them.
Lastly I have noted that there has been chunk of shares been bought consistently as US markets open every day since last 10 days..................

[bountyhunter] 23/2/2008 20:53

what stands out I think is that following the restructuring announced just a few days ago "The company is very cheap and people aren't blind to that" which is why I bought back in after being out for nearly two years;
...it's a gamble but one I'm prepared to take with a limited investment here.

[quraishim] 23/2/2008 19:48

This is what we have for the future.....or to a predator:-

Revised Focus Vernalis will continue to exploit its proven innovative research capabilities utilising its suite of structure-based drug discovery technologies which are employed in accelerating Vernalis' internal drug discovery programmes and for third party collaboration programmes in the CNS and oncology fields. Vernalis' clinical development portfolio comprises six product candidates, two of which are being developed under collaborative arrangements. The status of the four product candidates in which Vernalis is investing its own funds is as follows: • V1512 (Parkinson's disease). Results are expected shortly from a pharmacokinetic-pharmacodynamic study to evaluate the plasma profiles of repeated doses of the drug compared with Carbidopa/L-Dopa prior to the evaluation of the drug in a Phase III programme. • V10153 (Ischemic stroke). V10153 is currently being evaluated in a Phase IIa study in patients who have recently suffered a stroke. Results from the study are expected at the end of 2008. • V3381 (Neuropathic pain). This product has successfully completed a Phase IIa trial which demonstrated that V3381 was generally well tolerated with good preliminary indications of efficacy. 3 • V24343 (Obesity). V24343 has successfully completed a Phase I study which showed that V24343 produced significant weight loss in overweight and mildly obese volunteers. Vernalis' R&D collaborations are not affected by the strategic restructuring. These comprise: • The collaboration with Biogen Idec to develop V2006 (currently in a Phase II programme), an A2A antagonist to treat Parkinson's disease. • The collaboration with Novartis to identify Hsp90 inhibitors to treat various cancers. AUY922, the lead compound from this collaboration, is currently being evaluated in a Phase I programme. • The three-year oncology drug discovery collaboration with Servier. Response to the FDA on Frova® In parallel with the loan settlement and restructuring, Vernalis and Endo are currently preparing their responses to the points that were raised by the FDA in its non-approvable action letter for the Supplemental New Drug Application (sNDA) for Frova for the treatment of menstrual migraine. Peter Fellner, Executive Chairman, comments: "I believe that the settlement of the outstanding loan, together with the extensive restructuring of the business, will create a platform that will enable us to rebuild significant shareholder value in the mid-term".

[quraishim] 23/2/2008 19:29

Analysts said that the restructuring paved the way for Vernalis to be bought. Sam Fazeli, senior research analyst at Piper Jaffray, said: "Looking at Vernalis, you now see a company where the CEO has left and where they've got rid of the Sword of Damocles hanging over their head by restructuring and giving themselves a long cash life. The company is very cheap and people aren't blind to that.
It will divest Apokyn® – currently marketed by Vernalis in the US for Parkinson's disease – and its US commercial operations, detailed discussions of which are currently ongoing with interested parties.
Vernalis will continue developing four product candidates in house – compounds for Parkinson's disease, ischemic stroke, neuropathic pain and obesity – and will carry on with collaborations with Biogen Idec (Parkinson's) and Novartis (cancer). The company noted that at the end of 2007 it had cash resources of £20.5 million.
Goldman Sachs said should Vernalis' management secure an arrangement with Endo Pharmaceuticals ensuring cash into 2009-2010, or demonstrate a willingness to consider other strategic alternatives, this would also lift the shares, in its view. Further still, the broker said it thinks there are a number of assets which management could exploit to strengthen its balance sheet further and, should this happen, it would expect the shares to re-rate.

[bountyhunter] 23/2/2008 17:38

you need to pay for the level 3 service on advfn to see all buys/sells

[4screws] 23/2/2008 16:53

cheers quraishim, my only thought was that anyone sitting on the fence, whio shouldn't be buying or selling on sentiment anyway would be getting a distorted view, any way onwards and upwards I say. I think gouing foprward as the company disposes of other parts and raises revenue the market will see this for the true potential that it has and I think the frova revenues may come quicker than we think and that will sustain the cash burn, all in my opinion.

[quraishim] 23/2/2008 12:18

4screws...yes all my buys were shown on the plus market....dont know why it does not show on advfn, really not too bothered....

[bountyhunter] 23/2/2008 10:52

maybe on the plus market?
there is a website where you can see those trades
...got to rush off out now